Lucida Medical and Hampshire Hospitals NHS Foundation Trust in the U.K. are highlighting results from a clinical study regarding Lucida's Prostate Intelligence (Pi) AI software for prostate cancer detection.
The five-year study, called Prostate AI Research -1 (PAIR-1), has shown that the software -- in use in NHS and European hospitals -- demonstrates performance equivalent to that of expert radiologists for identifying the disease.
PAIR-1 is a collaboration between Lucida Medical and eight NHS Trusts and has included data from more than 2,000 patients to develop, train, and validate the software, which analyzes MRI scans for clinically significant prostate cancer.
Results from the research were presented by Francesco Giganti of University College London at the recent ECR meeting in Vienna. They were also published 28 February in the European Journal of Radiology.
"[Our] research found that Pi is non-inferior to multidisciplinary team-supported radiologists across a validation set of sequential cases from six NHS hospitals with a wide range of MRI scanner types," Giganti said in a statement released by the firm. "This is the first time that a commercial AI for prostate MRI has been tested on diverse, real-world data."
